- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Akums Drugs and Pharmaceuticals Limited has entered into an exclusive Master Sales Agreement with Caregen Co., Ltd, a leading South Korean biotechnology firm specializing in peptide research. This five-year agreement grants Akums the exclusive rights to sell specific Caregen products in India. Under this arrangement, Akums will also handle the packaging, marketing, and distribution of these products, which can be sold under various trademarks.
Caregen's offerings include over 600 innovative peptides developed for various applications in biotechnology, ranging from cosmeceuticals to pharmaceuticals, contributing to significant revenue generation. This partnership enables Akums to enhance its product portfolio and market presence, indicating a positive outlook for future sales growth. Investors should watch closely for developments related to this collaboration and its impact on revenue streams.
All announcements from Akums Drugs and Pharmaceuticals Limited